# A Safety, Efficacy and Tolerability Study of SEP-225289

> **NCT00584974** · PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 523 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** SEP-225289
- **DRUG:** SEP-225289
- **DRUG:** Venlafaxine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00584974
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 523 (ACTUAL)
- **Last updated:** 2012-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00584974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00584974, "A Safety, Efficacy and Tolerability Study of SEP-225289". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00584974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*